The Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade - Wassim Abida

January 31, 2019

Wassim Abida joins Charles Ryan in a discussion on a JAMA Oncology published paper on the Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. Wassim details the prevalence of MSI-H/dMMR prostate cancer and the clinical benefit of anti–PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy in this molecularly defined population. The discussion includes the therapeutic approach to treatment and the role of panel sequencing, the feasibility of finding BRCA mutations, and possible reasons for MSI high patients to not respond to immunotherapy.

Biographies:
Wassim Abida, MD, Ph.D. Medical Oncologist, Memorial Sloan Kettering Cancer Center

Charles J. Ryan, MD, the President and Chief Executive Officer of The Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. Charles J. Ryan is an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced prostate cancer. Dr. Ryan joined the PCF from the University of Minnesota, Minneapolis, where he served as Director of the Hematology, Oncology, and Transplantation Division in the Department of Medicine. He also served as Associate Director for Clinical Research in the Masonic Cancer Center and held the B.J. Kennedy Chair in Clinical Medical Oncology.

email news signup